World Health Organization Issues Global Guidelines for the Use of GLP-1 Drugs in Obesity Management
The World Health Organization (WHO) has released its first global guidelines on the use of glucagon-like peptide-1 (GLP-1) receptor agonists for treating obesity in adults. While acknowledging the effectiveness of these drugs in weight loss and metabolic health, the WHO emphasizes that they must be used alongside intensive behavioral interventions, diet, and physical activity. The guidelines highlight the need for equitable access, as these drugs are currently expensive and often unavailable in low- and middle-income countries. In India, experts suggest that insurance coverage and the development of generic versions are crucial for widespread benefit.
Key Points
- GLP-1 therapies are recognized as effective tools for obesity management but are not a standalone solution.
- The WHO recommends these drugs for adults, excluding pregnant women, and stresses the importance of lifestyle changes.
- Obesity is a complex chronic disease linked to cardiovascular issues, type 2 diabetes, and certain cancers.
- High costs and limited long-term data on efficacy after discontinuation remain significant challenges for global adoption.
Exam Facts
- GLP-1 stands for Glucagon-Like Peptide-1.
- Global economic cost of obesity is predicted to reach $3 trillion annually by 2030.
- WHO guidelines were released on December 1, 2025.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.